Search Results
Your search for The ,The matches 35814 pages
Showing 1 - 50HCC: LLM Advice and Treatment Concordance
Commonly used large language models (LLMs) were able to provide appropriate, guideline-aligned treatment recommendations for patients with straightforward cases of early-stage hepatocellular carcinoma; however, greater disagreement with physician recommendations was seen in cases of late-stage...
What Is Causing a Rise in Early-Onset Gastrointestinal Cancers, Including Pancreatic Cancer?
Although it’s been widely reported for years that colorectal cancer incidence has been increasing among younger adults under age 50 by between 1% and 2% annually since the mid-1990s,1 two new studies by Kimmie Ng, MD, MPH, Associate Chief of the Division of Gastrointestinal Oncology and Founding...
Breast Cancer Risk May Be Linked to Physical Activity Levels in Adolescence
Recreational physical activity may be associated with breast tissue composition and oxidative stress levels in adolescent girls, independent of body fat percentages, according to research findings published in Breast Cancer Research. “The importance and urgency of this research are underscored by...
ctDNA Positivity After Neoadjuvant T-DM1 May Predict HER2-Positive Breast Cancer Recurrence
Excluding skin cancers, breast cancer is the most commonly diagnosed cancer among women in the United States, accounting for about 30% of all new female cancers each year. In 2026, the American Cancer Society estimates that 322,000 new cases of invasive breast cancer and about 61,000 new cases of...
Global Cancer Survival Gaps Assessed Using a Country-Level Machine-Learning Framework
A machine-learning model has calculated country-specific cancer mortality-to-incidence ratios and evaluated the factors that contribute the most to each country's survival gaps. Additionally, the artificial intelligence (AI) tool mapped out actions each country could take to improve cancer...
Can a Genetic Variant Affect the Efficacy of Abiraterone?
Data from a major clinical trial from the Alliance for Clinical Trials in Oncology have uncovered a genetic factor that may inform how to optimize the dosing of abiraterone, a widely used hormonal treatment for advanced prostate cancer. Published by Norton et al in Clinical and Translational...
Dina Ioffe, MD, on Disparities in HCC: Do They Affect Systemic Care?
Dina Ioffe, MD, of Fox Chase Cancer Center, describes the results of an analysis that sought to determine how race/ethnicity, insurance status, and socioeconomic status may affect patterns of systemic treatment for metastatic hepatocellular carcinoma (HCC) (Abstract 489).
SCLC: Small Study Tests Efficacy of CTCs in Predicting Response to Tarlatamab
A research team has discovered that a particular marker on circulating tumor cells (CTCs) may indicate whether a patient with small cell lung cancer (SCLC) will experience a lasting response to tarlatamab-dlle, a newly approved immunotherapy. The findings, which were published by Mishra in Cancer...
Genetic Predisposition to Higher Body Mass Index Linked to Mortality After Breast Cancer
In an observational cohort study published in JAMA Network Open, Bodelon et al examined whether inherited susceptibility to excess body weight influences long-term survival among breast cancer survivors. Using a polygenic score for body mass index (BMI), the investigators sought to determine...
Improved Contralateral Breast Cancer Risk Knowledge With Personalized Counseling Tool
Patients with unilateral breast cancer who underwent quantitative counseling with a personalized tool incorporating genetic testing results were better informed of their contralateral breast cancer risk compared with those who received standard counseling, according to results from the GET FACTS...
Machine Learning–Guided ‘Optical Biopsy’ Accurately Identifies Malignant Lung Nodules Intraoperatively
In a cohort study reported in JAMA Network Open, Azari et al evaluated whether machine learning–guided analysis of intraoperative molecular imaging (IMI) data could accurately and rapidly determine the malignant potential of indeterminate lung nodules during surgery. The study was undertaken to...
Machine Learning Approach Accelerates Discovery of Novel CDK9 Inhibitors
A virtual screening campaign using machine learning identified molecules with potential for development as novel CDK9 inhibitors for the treatment of cancer, according to early research findings published in Biomolecules. Integration of artificial intelligence (AI) into the drug discovery phase...
Breast Cancer Recurrence Risk Determined by Deep Learning Model Trained on Histopathologic Slides
A deep learning model demonstrated the ability to predict breast cancer recurrence risk and possible benefit from the addition of chemotherapy based on histopathologic images rather than genomic testing in patients with hormone receptor–positive, HER2-negative breast cancer, according to findings...
Novel Endocrine Therapy, Giredestrant, Improves Invasive Disease–Free Survival in Estrogen Receptor–Positive, HER2-Negative Early Breast Cancer
Giredestrant, a next-generation oral selective estrogen receptor degrader (SERD) and full antagonist, significantly improved invasive disease–free survival as adjuvant treatment for patients with estrogen receptor–positive, HER2-negative early breast cancer compared with standard-of-care endocrine...
Nivolumab Plus AVD Reduces Disease Progression Risk in Adolescents With Advanced Classical Hodgkin Lymphoma
A combination of nivolumab with AVD chemotherapy (doxorubicin, vinblastine, and dacarbazine) demonstrated a significant reduction in the risk of disease progression or death compared with brentuximab vedotin plus AVD in adolescent patients with newly diagnosed advanced classical Hodgkin lymphoma,...
Whole-Genome Sequencing–Based Classifier Better Predicts Homologous Recombination Deficiency Across Cancer Types
A whole-genome sequencing–based classifier demonstrated greater performance for predicting homologous recombination deficiency (HRD) across cancer types than standard assays, which in turn determined which patients with cancer would benefit from treatment with PARP inhibitors, according to findings ...
ACS Report Shows 5-Year Survival Rate for All Cancers Combined Has Reached 70%
New data published by Siegel et al in the American Cancer Society’s (ACS) Cancer Statistics, 2026 report show that, for the first time, the 5-year survival rate for all cancers combined has reached 70% for individuals diagnosed during 2015 to 2021 in the United States. In addition, those diagnosed...
Can DNA Testing of Colorectal Polyps Improve Insight Into Genetic Risks?
It is estimated that hereditary factors play a role in about 5% to 10% of colorectal cancer cases, with a higher prevalence of hereditary factors seen in younger patients. Many colorectal polyps are considered potential precursors to cancer: at least 10 polyps in individuals younger than 60 years...
Multiple Myeloma: Sex Differences in Etiology and Clinical Presentation
Rates of multiple myeloma, the second most common blood cancer in the United States, are increasing and are twice as high in men than in women. A new study published by Ong et al in the journal Cancer provides insights that may help to explain this disparity. To investigate the sex difference in...
Pirtobrutinib vs Ibrutinib in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
In a phase III trial (BRUIN CLL-314) reported in the Journal of Clinical Oncology, Woyach et al found that pirtobrutinib was associated with a noninferior objective response rate vs ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma, while also being associated with...
Addition of Nivolumab to Docetaxel in ARPI-Pretreated, Chemotherapy-Naive Advanced Prostate Cancer
As reported in The Lancet Oncology by Fizazi et al, the phase III CheckMate 7DX trial showed no progression-free or overall survival benefit with the addition of nivolumab to docetaxel in patients with androgen receptor pathway inhibitor (ARPI)–pretreated and chemotherapy-naive metastatic...
Addition of Postoperative Nivolumab to Cisplatin and Radiotherapy in High-Risk Locally Advanced HNSCC
In a phase III trial (GORTEC 2018-01, NIVOPOST-OP) reported in The Lancet, Bourhis et al found that the addition of adjuvant nivolumab to cisplatin and radiotherapy improved disease-free survival in patients with high-risk, resected, locally advanced squamous cell carcinoma of the head and neck...
FDA Increases Flexibility on Requirements for Cell and Gene Therapies
The U.S. Food and Drug Administration (FDA) has announced it is sharing information about the agency’s flexible approach to overseeing chemistry, manufacturing, and control (CMC) requirements for cell and gene therapies (CGTs). The agency’s more flexible approach has been, and is expected to...
Anaplastic Glioma: Concurrent vs Adjuvant Temozolomide
As reported in The Lancet Oncology by van den Bent et al, the final analysis of the phase III CATNON trial has shown continued overall survival benefit with radiotherapy followed by 12 cycles of adjuvant temozolomide in patients with newly diagnosed 1p/19q non–co-deleted anaplastic gliomas;...
Molecular Profile–Based Adjuvant Treatment in High-Intermediate Risk Endometrial Cancer
In a European phase III trial (PORTEC-4a) reported in The Lancet Oncology, van den Heerik et al found that molecular profile–based adjuvant treatment produced favorable results in women with high-intermediate risk endometrial cancer and allowed patients with favorable risk to be spared adjuvant...
MajesTEC-3: ‘Unprecedented’ Benefit in Previously Treated Multiple Myeloma
For patients with previously treated multiple myeloma, the greatest risk reduction yet achieved in a phase III clinical trial was reported with the BCMA-directed CD3 T-cell engager teclistamab-cqyv plus daratumumab and hyaluronidase-fihj. Treatment with this combination resulted in an 83% reduction ...
Daniela Molena, MD, on Surgical Journey in the MATTERHORN Trial
Daniela Molena, MD, of Memorial Sloan Kettering Cancer Center, discusses a comparison of the surgical journeys of patients with resectable gastric/gastroesophageal adenocarcinoma who either received fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) plus durvalumab or FLOT plus placebo in...
Refractory LBCL: CD19-Targeting CAR T-Cell Therapy Plus Rituximab
A dual-antigen targeting combination of the CD19-targeting chimeric antigen receptor (CAR) T-cell therapy axicabtagene ciloleucel plus the CD20-targeting agent rituximab led to durable responses and reduced relapses in patients with refractory large B-cell lymphoma (LBCL), according to findings...
Can KDM6A Mutations Help Guide Treatment Selection in Bladder Cancer?
Mutations in KDM6A have been identified as a regulator of therapeutic responses in advanced bladder cancer, sensitizing tumors to anti–PD-1 immune checkpoint inhibition but resisting cisplatin chemotherapy, according to early research published in Nature Communications. Based on this and further...
Elena Elimova, MD, on HER2-Positive Gastroesophageal Cancer: Zanidatamab Plus Chemotherapy
Elena Elimova, MD, of Princess Margaret Cancer Centre, presents findings from the primary analysis of the phase III HERIZON-GEA-01 trial, which evaluated zanidatamab, a dual HER2-targeted bispecific antibody, plus chemotherapy with or without the PD-1 inhibitor tislelizumab vs trastuzumab plus...
In Head-to-Head Comparison, Fixed-Duration Treatment Noninferior to Continuous for Previously Untreated CLL
Based on the phase III CLL17 trial, a fixed duration of targeted treatment demonstrated noninferiority to continuous treatment with respect to progression-free survival in previously untreated patients with chronic lymphocytic leukemia (CLL). The findings were presented at the Plenary Session of...
Researchers Create Immune Cell Atlas of Bone Marrow in Patients With Multiple Myeloma
Scientists at several institutions across the country, in partnership with the Multiple Myeloma Research Foundation (MMRF), have helped generate the largest single-cell immune cell atlas of the bone marrow in patients with multiple myeloma. The findings, published by Pilcher et al in Nature Cancer, ...
Small Study Examines Potential of Artificial Saliva in Patients With Head and Neck Cancer
An artificial saliva in the form of a mouthwash, produced with a protein extracted from sugarcane and modified in a laboratory, may aid in treating hyposalivation among patients with head and neck cancer, a new study has found. Radiotherapy delivered very close to the mouth can destroy salivary...
Are Food Preservatives Linked to Increased Cancer Risk?
Higher intake of food preservatives, widely used in industrially processed foods and beverages to extend shelf life, is associated with a modestly increased risk of cancer, according to the results of a French study published by Hasenböhler et al in The BMJ. While further research is needed to...
Elizabeth Smyth, MD, on FLOT Administration in the MATTERHORN Trial
Elizabeth Smyth, MD, of the Oxford NIHR Biomedical Research Centre, Churchill Hospital, presents findings from an analysis of the MATTERHORN trial, a phase III study that examined fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) plus durvalumab in patients with resectable...
Samuel J. Klempner, MD, on Advanced Gastric/GEJ Cancer: Zolbetuximab Plus mFOLFOX6 and Nivolumab
Samuel J. Klempner, MD, of Massachusetts General Hospital, discusses results from the phase II ILUSTRO trial, which evaluated the combination of the anti-CLDN18.2 antibody zolbetuximab plus mFOLFOX6 and nivolumab in patients with CLDN18.2-positive; HER2-negative; locally advanced, unresectable, or...
Investigational PSMA-Targeted Radioligand Reduced Off-Target Uptake in Prostate Cancer Models
A novel prostate-specific membrane antigen (PSMA)-targeted radioligand therapy shows the potential to enhance therapeutic effects for patients with PSMA-positive prostate cancer while eliminating the potential for severe adverse effects such as xerostomia, according to preclinical findings...
Early Results Show Pirtobrutinib Matches Ibrutinib in BTK Inhibitor-Naive CLL
In the phase III BRUIN CLL-314 trial, response rates were found to be as good with the noncovalent Bruton's tyrosine kinase (BTK) inhibitor pirtobrutinib as with ibrutinib in both patients with treatment-naive and relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic...
Ghassan K. Abou-Alfa, MD, on Tremelimumab Rechallenge in Unresectable HCC: Safety Outcomes
Ghassan K. Abou-Alfa, MD, of Memorial Sloan Kettering Cancer Center, outlines an assessment of baseline characteristics and safety outcomes in HIMALAYA trial participants who were rechallenged with tremelimumab after being treated with the STRIDE regimen (single dose of tremelimumab plus...
Ghassan K. Abou-Alfa, MD, on a Novel First-Line Regimen for Unresectable HCC Under Study
Ghassan K. Abou-Alfa, MD, of Memorial Sloan Kettering Cancer Center, reviews the goals of the upcoming phase III ARTEMIDE-HCC01 trial, which will examine the efficacy and safety of rilvegostomig (a novel bispecific anti–PD-1/anti-TIGIT antibody) plus bevacizumab with or without tremelimumab as...
Benefit of Azacitidine Plus Venetoclax Confirmed in AML
The combination of the hypomethylating agent azacitidine and the BCL2 inhibitor venetoclax is an established regimen in older, unfit patients with acute myeloid leukemia (AML). Now, a phase II randomized trial indicates potential for less intensive therapy in the newly diagnosed fit population. In...
ACS Guidelines for Cervical Cancer: Self-Collected HPV Testing Now Included
Self-collection of vaginal samples for human papillomavirus (HPV) testing is now being considered an acceptable, recommended option for cervical cancer screening, per recent updates to the American Cancer Society's (ACS) guidelines published in CA: A Cancer Journal for Clinicians CA: A Cancer...
Atezolizumab vs Placebo With Bevacizumab and Nonplatinum Chemotherapy for Recurrent Ovarian Cancer
As reported in the Journal of Clinical Oncology by Harter et al, the final results of a European phase III trial (AGO-OVAR 2.29/ENGOT-ov34) showed no significant overall or progression-free survival benefit with the addition of atezolizumab to bevacizumab and nonplatinum chemotherapy in patients...
Using AI to Ensure That All Patients With Cancer Have Access to Precision Oncology Care
Steve Brown, Founder and Chief Executive Officer of CureWise (curewise.com), an artificial intelligence (AI)-driven patient advocacy app, describes his year-long quest to understand a series of symptoms that ultimately led to a diagnosis of light chain (AL) amyloidosis—a disease closely related to ...
Cancer Mortality According to Occupation in the United States
In a study reported in The Lancet Oncology, Lesinski et al identified cancer mortality rates according to the occupation of U.S. adults aged 20 to 64 years between 2020 and 2023. Study Details The study used information on cancer deaths for 22 main cancer sites from 2020 to 2023 among adults aged...
Addition of Epcoritamab to Lenalidomide Plus Rituximab in Relapsed or Refractory Follicular Lymphoma
As reported in The Lancet by Falchi et al, an interim analysis of the phase III EPCORE FL-1 trial has shown that the addition of the bispecific antibody epcoritamab (for B-cell CD20 and T-cell CD3 antigens) to lenalidomide plus rituximab improved the objective response rate and progression-free...
Adjuvant Epirubicin Plus Cyclophosphamide Followed by Taxane With or Without Carboplatin in Early-Stage Triple-Negative Breast Cancer
In a Chinese phase III trial (RJBC 1501) reported in the Journal of Clinical Oncology, Chen et al found that the addition of carboplatin to adjuvant epirubicin plus cyclophosphamide followed by taxane chemotherapy significantly improved disease-free survival in patients with early-stage...
HER2-Positive Gastroesophageal Cancer: Zanidatamab Plus Chemotherapy Prolongs Progression-Free Survival
Results from a new phase III study showed that in patients with HER2-positive metastatic gastroesophageal adenocarcinoma, the combination of the dual HER2-targeted bispecific antibody zanidatamab and chemotherapy, with or without the PD-1 inhibitor tislelizumab, extended progression-free survival....
Study Finds Patients With Colon Cancer and Obesity Receiving GLP-1 RAs Had Significantly Reduced Risk of Mortality
Colon cancer is among the leading causes of cancer-related morbidity and mortality both in the United States and globally, with alarming increases in incidence and mortality among younger adults. Although the exact causes of these increases are unknown, lifestyle factors—including poor diet,...
Impact of Physical Activity on Fatigue, Quality of Life in Nonmetastatic Colorectal Cancer
Greater levels of physical activity in the first 2 years after a colorectal cancer diagnosis were associated with reduced cancer-related fatigue and improved quality of life in patients with nonmetastatic disease, according to findings from a prospective, multicenter, longitudinal analysis from a...
